January 1, 2021
December 31, 2020
December 25, 2020
Delta is helping in the global effort to distribute COVID-19 vaccines by offering four tailored pharmaceutical shipping options which meet the temperature requirements for vaccines. With large warehouses and cooler facilities in major cities across the United States, Delta has the necessary infrastructure in place to support COVID-19 vaccine shipments. At Yourway, we appreciate Delta's help in the global fight against the pandemic and look forward to join in the massive vaccine distribution effort.
December 24, 2020
With one of the biggest logistical challenges in recent times ahead of the pharmaceutical industry and its supply chain partners, both must reimagine the way vaccines will be distributed in the future. Instead of completely redesigning its supply chain, which would take months or even years, a better path would be to collaborate across the global supply-chain community to excess capacity in other industries. Corporate and military supply chains are exponentially more powerful and collaborations across industries hold the key to a quick, safe and effective distribution of future COVID-19 vaccines. Yourway looks forward to supporting the massive vaccine distribution effort.
December 23, 2020
The FDA emergency authorization for Pfizer's COVID-19 vaccine has led to a sharp increase in ultra-cold freezer sourcing. These freezers will be important in achieving cold temperature requirements during vaccine production, shipping and distribution. Demand for dry ice has also increased by 185% in Q3 from 2019 to 2020. As an organization providing temperature-controlled transportation across the globe, Yourway is paying close attention to this development.
Pharmaceutical and food companies are losing millions of dollars a year due to failures in the cold chain. Cloudleaf, a supply chain tracking solutions firm, surveyed 210 U.S. supply chain professionals and found that 92% can't trust the data they have on products traveling through their supply chains. The problem is taking on a higher profile as the cold chain becomes more and more important in the distribution of the COVID-19 vaccine. As an organization providing temperature-controlled transportation across the globe, Yourway is always looking for ways to become more efficient.
December 21, 2020
Kaye has introduced a new vaccine temperature logger to ensure the validation and safety of the cold chain. The new log allows data to be transported to a mobile device with a quick swipe of an NFC device, giving actual live-data of the ultra-cold temperatures necessary to store and transport COVID-19 vaccines safely. As an organization providing temperature-controlled transportation across the globe, Yourway cares deeply about the cold chain packaging market and appreciates this new introduction.
December 18, 2020
Hoth Therapeutics, Inc. announced it has received Human Research Ethics Committee (HREC) clearence to commence the first cohort of the Phase 1b clinical trial of BioLexa Lotion. The lotion will be used for the treatment of mild to modrate atopic dermatitis in Australia and is expected to treat the first subject in early 2021, with top-line data from the first cohort of the trial expected in the first quarter of 2021. Pending the succesful completion of the Phase 1b trial, the company intends to conduct a Phase 2 trial with adult and adolescent patients to continue clinical investigation of the lotion's efficacy. Yourway is well positioned to support clinical trials in dermatology.
December 17, 2020
Ambrx has presented new results on their lead program ARX788, a homogeneous and highly stable, site-specific antibody drug conjugate targeting HER2 positive cancers. "[...] Phase 1 studies demonstrated promising antitumor activity in heavily pre-treated cancer patients at the recommended Phase 2 dose", said Joy Yan, MD, PhD, Ambrx Chief Medical Officer. The randomized controlled Phase 2/3 has treated 22 subjects and continues to enroll patients quickly. Yourway is delighted about the positive results and continues to support the fight against cancer.
IBM's Security X-Force, the company's cloud-based threat intelligence platform that allows costumers to consume, share and act on threat intelligence, recently urged Operation Warp Speed (OWS) organizations to review a report that identified attackers targeting the COVID-19 vaccine cold chain. IBM security officials believe the phishing operation holds the potential hallmarks of nation-state tradecraft and targeted executives and key global organizations associated with the Vaccine Alliance's Cold Chain Equipment Optimization Platform (CCEOP) program. As an organization providing temperature-controlled transportation across the globe, Yourway is paying close attention to heightened security needs and appreciates the effort of IBM's Security X-Force.
SpendEdge's new BioPharma packaging market research report indicates a cumulative growth between 2020-2024. The report helps understand risk management and sustainability strategies, incumbent supplier evaluation metrics and pricing outlook and factors influencing the precurement process. It also offers insights into regional spend dynamism and factors impacting costs, total cost of ownership, cost-saving opportunites and supply chain margins and pricing models. As an organization providing temperature-controlled transportation across the globe, Yourway cares deeply about the cold chain packaging market.
December 14, 2020
With the development of COVID-19 vaccines in record time, distribution of the doses might be the most complex logistical challenge since World War II, according to Andrew Boyle of Boyle Transportation. Supply chain challenges have already prompted Pfizer to half production of the number of vaccines produced before 2021 and the American Trucker Association has sent letters to health and government committees to include the trucking industry's workforce in the prioritized access pools along with other essential workers. As an organization, Yourway looks forward to supporting the massive vaccine distribution effort.
Focusing on the Patient Experience in Clinical Trials with Ancillary Kitting Supplies